Richard M. Lush

4.2k total citations
78 papers, 3.3k citations indexed

About

Richard M. Lush is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard M. Lush has authored 78 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Molecular Biology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard M. Lush's work include Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (11 papers) and Cancer therapeutics and mechanisms (10 papers). Richard M. Lush is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (11 papers) and Cancer therapeutics and mechanisms (10 papers). Richard M. Lush collaborates with scholars based in United States, Malaysia and Ukraine. Richard M. Lush's co-authors include William D. Figg, Dmitry I. Gabrilovich, Anthony Neuger, Mayer Fishman, Scott Antonia, Daniel M. Sullivan, Donna Headlee, Edward A. Sausville, Eduardo M. Sotomayor and Bin Yu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Richard M. Lush

78 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard M. Lush United States	26	1.5k	1.4k	875	451	292	78	3.3k
Alberto Ballestrero Italy	32	1.7k 1.2×	1.5k 1.0×	711 0.8×	327 0.7×	308 1.1×	164	4.0k
Cody J. Peer United States	33	1.8k 1.2×	1.5k 1.1×	626 0.7×	559 1.2×	450 1.5×	156	4.0k
Dona Alberti United States	30	1.4k 0.9×	1.0k 0.7×	317 0.4×	419 0.9×	273 0.9×	90	2.8k
Maria Napolitano Italy	33	1.5k 1.0×	1.5k 1.0×	1.0k 1.2×	316 0.7×	180 0.6×	93	3.3k
Lisa A. Kottschade United States	31	995 0.7×	2.8k 1.9×	717 0.8×	612 1.4×	186 0.6×	123	3.9k
Claudia Friesen Germany	24	2.5k 1.7×	1.1k 0.7×	692 0.8×	197 0.4×	187 0.6×	40	3.5k
Arimichi Takabayashi Japan	29	1.8k 1.2×	1.8k 1.3×	1.0k 1.2×	501 1.1×	199 0.7×	75	4.0k
Yi Luo China	32	1.8k 1.2×	854 0.6×	587 0.7×	660 1.5×	169 0.6×	149	4.3k
Erin R. Gardner United States	25	1.5k 1.0×	1.1k 0.8×	226 0.3×	256 0.6×	281 1.0×	49	2.9k
William Westlin United States	24	1.2k 0.8×	545 0.4×	492 0.6×	211 0.5×	404 1.4×	65	3.0k

Countries citing papers authored by Richard M. Lush

Since Specialization

Citations

This map shows the geographic impact of Richard M. Lush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard M. Lush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard M. Lush more than expected).

Fields of papers citing papers by Richard M. Lush

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard M. Lush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard M. Lush. The network helps show where Richard M. Lush may publish in the future.

Co-authorship network of co-authors of Richard M. Lush

This figure shows the co-authorship network connecting the top 25 collaborators of Richard M. Lush. A scholar is included among the top collaborators of Richard M. Lush based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard M. Lush. Richard M. Lush is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trucco, Matteo, Julio C. Barredo, Jeffrey L. Goldberg, et al.. (2018). A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG‐asparaginase, and doxorubicin. Pediatric Blood & Cancer. 65(9). e27224–e27224. 29 indexed citations

Springett, Gregory M., Kazim Husain, Anthony Neuger, et al.. (2015). A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. EBioMedicine. 2(12). 1987–1995. 65 indexed citations

Stroh, Mark, Punam Sandhu, Jacqueline B. McCrea, et al.. (2014). Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation. The Journal of Clinical Pharmacology. 54(11). 1256–1262. 4 indexed citations

Komrokji, Rami S., Jeffrey E. Lancet, Arlene S. Swern, et al.. (2012). Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 120(17). 3419–3424. 47 indexed citations

Perkins, Janelle, Steven C. Goldstein, Jana L. Dawson, et al.. (2011). Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates. Clinical Cancer Research. 17(24). 7743–7753. 3 indexed citations

O’Neil, Bert H., Laura W. Goff, John Kauh, et al.. (2011). Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 29(17). 2350–2356. 110 indexed citations

Daud, Adil, Jana L. Dawson, Ronald C. DeConti, et al.. (2009). Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research. 15(7). 2479–2487. 78 indexed citations

Husain, Kazim, R François, Anthony Neuger, et al.. (2008). Pancreatic Tissue Distribution, Pharmacokinetics and Toxicity of Bioactive delta‐tocotrienol, a Potential Anti‐tumor Bioactive Food Component, in Mice. The FASEB Journal. 22(S1). 1 indexed citations

Moulder, Stacy L., Anthony Neuger, Jimin Choi, et al.. (2008). Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 113(10). 2646–2654. 15 indexed citations

10.

Simon, George R., Christopher R. Garrett, Stephen C. Olson, et al.. (2006). Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. Clinical Cancer Research. 12(15). 4645–4651. 22 indexed citations

11.

Samarasena, Jason, et al.. (2006). Individuals Homozygous for the H63D Mutation Have Significantly Elevated Iron Indexes. Digestive Diseases and Sciences. 51(4). 803–807. 18 indexed citations

12.

Rago, Randall, Albert Einstein, Richard M. Lush, et al.. (2003). Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 51(4). 297–305. 25 indexed citations

13.

Lush, Richard M., David L. Bartlett, H. Richard Alexander, et al.. (1999). Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. The Journal of Clinical Pharmacology. 39(4). 394–401. 36 indexed citations

14.

Senderowicz, Adrian M., Donna Headlee, Sherman F. Stinson, et al.. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.. Journal of Clinical Oncology. 16(9). 2986–2999. 338 indexed citations

15.

Lush, Richard M., David Venzon, Paul H. Duray, et al.. (1998). Elevated Carcinoembryonic Antigen in Patients with Androgen-Independent Prostate Cancer. Journal of Investigative Medicine. 46(2). 66–72. 17 indexed citations

16.

Lush, Richard M., Beverly Meadows, Antonio Tito Fojo, et al.. (1997). Initial Pharmacokinetics and Bioavailability of PSC 833, a P‐Glycoprotein Antagonist. The Journal of Clinical Pharmacology. 37(2). 123–128. 20 indexed citations

17.

Figg, William D., Nancy A. Dawson, Otis W. Brawley, et al.. (1996). Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer. Acta Oncologica. 35(6). 763–765. 8 indexed citations

18.

Lush, Richard M., et al.. (1996). Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treatment Reviews. 22(2). 105–118. 10 indexed citations

19.

Dawson, Nancy A., Richard M. Lush, Seth M. Steinberg, et al.. (1996). Suramin-induced neutropenia. European Journal of Cancer. 32(9). 1534–1539. 9 indexed citations

20.

Kroboth, Patricia D., et al.. (1995). Coadministration of Nefazodone and Benzodiazepines. Journal of Clinical Psychopharmacology. 15(5). 306–319. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact